Proviron vs Tamoxifen
Well Studied vs FDA Approved
avoid Mechanism-based · 64% Both Proviron and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Proviron Tamoxifen
Weight 304.47 Da 371.51 Da
Half-life ~12 hours ~5-7 days
Type DHT derivative (C20H32O2) Triphenylethylene-derived selective estrogen receptor modulator
Key Benefits
Proviron
01 Strong SHBG binding frees more circulating testosterone, enhancing TRT efficacy
02 Improved mood, motivation, confidence, and overall sense of well-being
03 Significant enhancement of libido and sexual function
04 Anti-estrogenic effect reduces the need for dedicated aromatase inhibitors
05 Harder, drier, more defined physical appearance without water retention
06 Minimal hepatotoxicity due to absence of 17-alpha alkylation
07 May improve sperm quality at low doses in subfertile men
08 Rapid onset of subjective well-being effects (often within days)
Tamoxifen
01 Blocks estrogen receptor signaling in breast tissue, preventing and treating gynecomastia
02 Stimulates LH and FSH production by antagonizing hypothalamic estrogen receptors
03 Restores endogenous testosterone production during post-cycle therapy
04 Partial estrogen agonist activity in bone preserves bone mineral density
05 Extremely long half-life allows for flexible dosing schedules
06 Decades of clinical use with a well-characterized safety and efficacy profile
07 Oral administration with no injections or reconstitution required
Side Effects
Proviron
Accelerated hair thinning or loss in those predisposed to male pattern baldness (DHT-mediated)
Mild suppression of endogenous testosterone at higher doses (though less suppressive than most AAS)
Oily skin and increased sebum production
Mild HDL cholesterol suppression with extended use
Increased body hair growth
Tamoxifen
Hot flashes and night sweats
Nausea or gastrointestinal discomfort
Mood swings, irritability, or emotional lability
Fatigue during initial weeks of use
Headache
Contraindications
Prostate cancer (active or history of androgen-sensitive prostate cancer)
Severe liver impairment (though hepatotoxicity risk is minimal)
Breast cancer in males
Hypersensitivity to mesterolone or any excipients
Women who are pregnant or may become pregnant (androgenic effects on fetus)
History of deep vein thrombosis, pulmonary embolism, or other thromboembolic events
Known hypersensitivity to tamoxifen citrate or any excipients
Concurrent warfarin or coumarin-type anticoagulant therapy (increased bleeding risk)
Pregnancy or planned pregnancy (category D -- known teratogenic risk)
Pre-existing endometrial hyperplasia or uterine cancer
Severe hepatic impairment
Research Evidence
Proviron Tamoxifen
Status Well Studied FDA Approved
References 5 studies 5 studies
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.